RESUMEN
The effects of recombinant thrombopoietin (TPO) alone and in combination with erythropoietin (EPO) and early-acting cytokines such as interleukin 3 (IL-3), stem cell factor (SCF) and GM-CSF on highly purified mobilized human CD34+ progenitor cells were studied in a serum-depleted culture system. Eight leukapheresis samples were cultured for seven days and analyzed; aliquots were replated and re-evaluated on day 12. Three-color flow cytometry was used together with morphologic analysis to determine proliferation and megakaryocytic or erythroid maturation. TPO alone was sufficient for cell survival and proliferation in serum-depleted medium. In the absence of other growth factors, almost all CD34+ cells differentiated along the megakaryocytic pathway within 12 days. Concomitantly, the progenitor cells gradually acquired the morphologic features of mature megakaryocytes. After exposure to TPO for one week, 50% of the cells still expressed CD34; by day 12 the remaining CD34+ cells (11%) were all coexpressing CD41. TPO alone did not support proliferation of glycophorin-A-positive cells. The addition of TPO to early-acting cytokines (EPO, GM-CSF, SCF and/or IL-3) not only increased the overall megakaryocyte expansion, but also generated a different maturation pattern of the CD41+ megakaryocyte progenitors. It further doubled the number of erythroid cells and c-kit+ cells in the second week of culture. Interestingly, the overall number of CD34+ cells was increased about fivefold when TPO was added to the early-acting cytokines, with a marked expansion of the CD34+/CD41+ and CD34+/CD117+ subpopulations. TPO can augment the pool of committed progenitors, thereby increasing the number of its own target cells and the number of EPO-responsive cells. These properties make TPO an interesting cytokine for the ex vivo expansion of human progenitor cells.
Asunto(s)
Eritropoyetina/farmacología , Células Madre Hematopoyéticas/citología , Células Madre Hematopoyéticas/inmunología , Trombopoyetina/farmacología , Antígenos CD34/sangre , Biomarcadores/sangre , División Celular/efectos de los fármacos , Movimiento Celular , Células Cultivadas , Medio de Cultivo Libre de Suero , Sinergismo Farmacológico , Quimioterapia Combinada , Eritropoyesis/efectos de los fármacos , Factor Estimulante de Colonias de Granulocitos y Macrófagos/farmacología , Hematopoyesis/efectos de los fármacos , Humanos , Interleucina-3/farmacología , Megacariocitos/citología , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/análisis , Proteínas Recombinantes/farmacología , Factor de Células Madre/farmacologíaRESUMEN
We report our observations with the cell line LW/SO, which was recently derived from the bone marrow of a patient with acute myeloid leukemia. Based on the morphological and histochemical examination, the leukemic cells were classified primarily as FAB type M4. However, 2 years later, in relapse, the cells changed their morphology and were hence specified as FAB type M2 (slightly positive for acid phosphatase and Sudan black). The cells established have now been in culture for approximately 11 months and display nearly 100% CD4/5/7/15/25/71/120a,b at varying densities. Some of them spontaneously and reversibly become either CD34 + /38- or CD34 - /38+, yet the majority of the cells remain negative for both. All attempts to separate the cells with a distinct phenotype by limiting dilution or sorting through a flow cytometer failed repeatedly. The subsets, enriched up to 98% (regardless of their primary immunophenotype CD34 - / 38-, CD34 + /38-, or CD34 - /38+), soon displayed a phenotypical constellation similar to that before sorting. The ratio of CD34- to CD34+ seems to be influenced by the cell density: The greater the cell-to-cell contact, the lower the percentage of CD34-expressing cells. Some of the cells apparently differentiate into T-cell phenotype and acquire CD3 and T-cell receptor (TCR) alpha/beta molecules. While the quantity of CD34-expressing cells significantly increased in the presence of dexamethasone (10(-7) M), and some of them additionally acquired CD33 antigen, the percentage of CD3-positive cells was enhanced by adding 1% DMSO in medium. In contrast, cytokines such as IL-1, IL-2, IL-3, IL-4, IL-6, G-CSF, GM-CSF, or SCF (c-kit ligand) altered neither the proliferation capacity nor the phenotypical constellation of LW/SO cells (each tested alone). Although normal karyotype was obtained from the bone marrow cells, the LW/SO cells revealed a homogeneous chromosomal composition of 45, X, -X, der(9) inv(9) (p12q13) del(9) (p22?). These data suggested that LW/SO cells might be the leukemic counterpart of putative pre-CD34-positive progenitors. In order to substantiate this assumption, we analyzed the expression of other so-called T-cell markers on CD34+ cells from peripheral blood stem cell aphereses of five patients who later underwent high-dose chemotherapy and subsequent stem cell retransfusion. These data clearly revealed that a considerable amount of CD34+ hematopoietic progenitors co-express CD2/4/(5)/(7)/25 at an early stage of differentiation, and support the notion that CD34-negative LW/SO cells with the surface markers CD4/5/7/25 are probably phenotypical representatives of pluripotent stem cell. Hence, not all CD34-negative populations with so-called T-cell surface markers should be considered T-cells; some may constitute the ancestor of CD34 antigen-expressing progenitors.
Asunto(s)
Antígenos CD , Diferenciación Celular , Células Madre Hematopoyéticas/inmunología , Células Madre Hematopoyéticas/ultraestructura , Células Tumorales Cultivadas , ADP-Ribosil Ciclasa , ADP-Ribosil Ciclasa 1 , Fosfatasa Ácida/análisis , Antígenos CD34/análisis , Antígenos de Diferenciación/análisis , Médula Ósea/ultraestructura , Comunicación Celular , Femenino , Humanos , Inmunofenotipificación , Cariotipificación , Leucemia Mieloide Aguda/inmunología , Leucemia Mieloide Aguda/patología , Glicoproteínas de Membrana , Persona de Mediana Edad , N-Glicosil Hidrolasas/análisis , Reacción del Ácido Peryódico de Schiff , Fenotipo , Linfocitos TRESUMEN
OBJECTIVE: To study the regulation of granulocyte macrophage colony stimulating factor (GM-CSF) production by human articular chondrocytes which may contribute to the local GM-CSF production encountered in rheumatoid joints. This growth factor induces human macrophages to migrate and proliferate, improves their accessory function and increases the expression of HLA-DR antigens on macrophages and macrophage-like synoviocytes. METHODS: GM-CSF was assayed by ELISA and a bioassay in cell and organ culture supernatants from human articular chondrocytes, by in situ hybridization, Northern blot analysis and affinity chromatography. RESULTS: Both interleukin 1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha) synergistically or additively stimulated chondrocytes to produce significant amounts of immunoreactive and bioactive GM-CSF with maximum values of 2928 pg/ml (p < 0.0001 both for IL-1 and/or TNF-alpha vs baseline). Affinity chromatography using specific monoclonal antibodies for human GM-CSF resulted in the purification of a chondrocyte derived 22-23 kDa protein. In situ hybridization demonstrated that the number of chondrocytes that expressed GM-CSF mRNA correlated well to the amount of GM-CSF secreted into the cultures. Transforming growth factor beta (TGF-beta) and to a lesser extent interferon-gamma (IFN-gamma) were able to decrease GM-CSF production induced by IL-1 and/or TNF-alpha. In contrast, basic fibroblast growth factor (FGF) in combination with IL-1 strongly increased GM-CSF secretion up to 8.5-fold. IFN-gamma, IL-6, TGF-beta, bFGF and IL-8 given alone failed to induce chondrocytes to produce GM-CSF. Steroids and low concentrations of cyclooxygenase inhibitors in general suppressed cytokine induced GM-CSF production. CONCLUSION: Our data demonstrate that both proinflammatory cytokines IL-1 and TNF-alpha induce an immunoreactive and biologically active GM-CSF by human articular chondrocytes that appears to be downregulated by TGF-beta and upregulated by FGF. GM-CSF produced locally by cartilage cells may be an important cytokine involved in the activation and proliferation of pannus cells, that can be modulated by interactions with cytokines present in the inflamed joints, thus possibly contributing to the chronic infiltration and destruction of cartilage in inflammatory joint diseases.
Asunto(s)
Cartílago Articular/metabolismo , Citocinas/farmacología , Factores de Crecimiento de Fibroblastos/farmacología , Factor Estimulante de Colonias de Granulocitos y Macrófagos/biosíntesis , Cartílago Articular/citología , Dinoprostona/farmacología , Factor Estimulante de Colonias de Granulocitos y Macrófagos/química , Factor Estimulante de Colonias de Granulocitos y Macrófagos/genética , Humanos , Interleucina-1/farmacología , Linfotoxina-alfa/farmacología , Antagonistas de Prostaglandina/farmacología , ARN Mensajero/metabolismo , Esteroides/farmacología , Factor de Necrosis Tumoral alfa/farmacologíaRESUMEN
The GM/SO cell line bears a high level of stem cell factor receptors (SCF-R) i.e. c-kit protein, and therefore constitutes a potential model for studying the regulation of this crucial receptor on myeloid cells. In this study we evaluated the effect of tumor necrosis factor alpha (TNF-alpha) on the expression of SCF-R by flow cytometry. In contrast to 1 hour of preincubation, the experiments carried out after 24 hours preincubation revealed that TNF-alpha, if added alone, reduced the density of SCF-R on GM/SO cells in a dose-dependent manner. However, if combined with GM-CSF, which per se downregulates the SCF-R on these cells as well, TNF-alpha antagonized the effect of GM-CSF and slightly increased the density of SCF-R. Yet the cells incubated for 24 hours in medium without cytokines invariably expressed a higher level of SCF-R than the cells incubated in the presence of TNF-alpha and GM-CSF, either alone or in combination. In contrast to these cytokines, stem cell factor (SCF), which was also tested simultaneously in all experiments, downregulated its own natural receptor on these cells also after a preincubation of 1 hour. Furthermore, prolonged exposure of GM/SO cells to TNF-alpha for 5-7 days yielded a monocyte-macrophage-like morphology of some cells as these cells displayed an apparent glass and plastic adherence. In contrast, no such morphological changes could be observed in the presence of GM-CSF or SCF.
Asunto(s)
Células Madre Hematopoyéticas/metabolismo , Proteínas Proto-Oncogénicas/metabolismo , Proteínas Tirosina Quinasas Receptoras/metabolismo , Receptores del Factor Estimulante de Colonias/metabolismo , Factor de Necrosis Tumoral alfa/fisiología , Diferenciación Celular , Línea Celular , Regulación hacia Abajo , Factor Estimulante de Colonias de Granulocitos y Macrófagos/metabolismo , Factores de Crecimiento de Célula Hematopoyética/fisiología , Células Madre Hematopoyéticas/citología , Humanos , Proteínas Proto-Oncogénicas c-kit , Factor de Células MadreRESUMEN
By employing a monoclonal antibody against the stem cell factor receptor (SCF-R), c-kit oncogene product, we analysed in flow cytometric technique the density of SCF-R on GM/SO cells which were incubated under various culture conditions. These experiments revealed that there is an inverse correlation between the SCF-R density on the cells and the doses of granulocyte-macrophage colony-stimulating factor (GM-CSF) in culture medium; the lower the dose, the higher the density of SCF-R on the cells. More detailed analyses showed that, in contrast to SCF which rapidly downregulates its own receptor, GM-CSF does not alter the measurable level of SCF-R in an exposition period of 60 minutes, which suggests that the internalization or shedding of the receptor is not the mechanism of action. Since the most striking difference regarding density of SCF-R between GM-CSF-treated and untreated cells was observed on day 2, the modulation of c-kit oncogene protein by GM-CSF likely occur prior to expression of protein onto the cell surface. In order to exclude the possibility that altered cell viability due to insufficient GM-CSF content in culture medium might be responsible for the increased SCF-R densities on GM-CSF-dependent cells, we subsequently generated a GM-CSF-independent subclone which still responded to GM-CSF as well as the dependent did. The experiments carried out with this subclone confirmed the results presented above. Thus our data suggest that GM-CSF is directly involved in the regulation of SCF receptor density on GM/SO cells.
Asunto(s)
Factor Estimulante de Colonias de Granulocitos y Macrófagos/farmacología , Factores de Crecimiento de Célula Hematopoyética/metabolismo , Células Madre Hematopoyéticas/efectos de los fármacos , Proteínas Proto-Oncogénicas/biosíntesis , Proteínas Tirosina Quinasas Receptoras/biosíntesis , Receptores del Factor Estimulante de Colonias/biosíntesis , Anticuerpos Monoclonales/inmunología , Diferenciación Celular/efectos de los fármacos , División Celular/efectos de los fármacos , Línea Celular Transformada , Regulación hacia Abajo/efectos de los fármacos , Humanos , Proteínas Proto-Oncogénicas/inmunología , Proteínas Proto-Oncogénicas c-kit , Proteínas Tirosina Quinasas Receptoras/inmunología , Receptores del Factor Estimulante de Colonias/inmunología , Proteínas Recombinantes/farmacología , Factor de Células MadreRESUMEN
To evaluate the effect of colony-stimulating factors and interferon gamma on the oxidative burst capacity of neutrophils in chronic granulomatous disease (CGD) we studied the neutrophils of a patient with variant CGD both from peripheral blood and from bone marrow culture on day 7 and 14. The results revealed that preincubation of peripheral neutrophils for 24 h in medium containing recombinant human granulocyte colony-stimulating factor (rhG-CSF), recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF), and recombinant human interferon gamma (rhIFN-gamma) alone or in combination did not improve the maximal oxidative burst activity measured by MTT assay. The colonies of this patient formed in agar assay were either composed of predominantly nitroblue tetrazolium (NBT)-positive cells or completely unable to reduce NBT. Despite variable colony numbers in the presence of different cytokines, the rate of NBT-positive colonies was less than 17% of the total number of colonies. However, more than 72% of the colonies were NBT positive in controls. In liquid culture, bone marrow cells yielded a comparable rate of NBT-positive and -negative populations at day 7. These data indicate that rhG-CSF, rhGM-CSF, and rhIFN-gamma alone or rhG-CSF and rhGM-CSF in combination with rhIFN-gamma are not able to reconstitute the oxidative burst defect in CGD in vitro. Indeed, regarding colony-forming capacity, the bone marrow cells from the patient responded to CSFs as well as those from control donors did. This fact may warrant the administration of hematopoietic growth factors, at least in variant CGD, in order to enhance the absolute number of functionally normal neutrophils.
Asunto(s)
Médula Ósea/patología , Factor Estimulante de Colonias de Granulocitos/farmacología , Factor Estimulante de Colonias de Granulocitos y Macrófagos/farmacología , Enfermedad Granulomatosa Crónica/patología , Interferón gamma/farmacología , Neutrófilos/fisiología , Adulto , División Celular/fisiología , Células Clonales/citología , Femenino , Humanos , Recuento de Leucocitos/efectos de los fármacos , Proteínas Recombinantes , Estallido Respiratorio/efectos de los fármacosRESUMEN
Based on the granulocyte-macrophage colony-stimulating factor (GM-CSF) dependency of a newly established human myeloid cell line GM/SO, we developed a highly specific and sensitive bioassay for human GM-CSF. The presence of bioactive GM-CSF could be determined by measuring the formazan concentration produced from MTT by the cells that survived and proliferated in the presence of either natural or recombinant human GM-CSF. With this assay we were able to quantify the level of GM-CSF in two human sera as well as in conditioned media from human bladder cell carcinoma cell line 5637, a human fibroblast line, and phytohemagglutinin-stimulated peripheral blood mononuclear cells. The sensitivity of the assay allows measurement of concentrations of GM-CSF as low as 0.1 U/ml.
Asunto(s)
Bioensayo , Factor Estimulante de Colonias de Granulocitos y Macrófagos/análisis , División Celular , Supervivencia Celular , Medios de Cultivo , Citocinas/farmacología , Ensayo de Inmunoadsorción Enzimática , Fibroblastos/metabolismo , Formazáns/metabolismo , Factor Estimulante de Colonias de Granulocitos y Macrófagos/sangre , Factor Estimulante de Colonias de Granulocitos y Macrófagos/farmacología , Humanos , Leucemia Mielógena Crónica BCR-ABL Positiva/patología , Leucocitos Mononucleares/metabolismo , Fitohemaglutininas/farmacología , Proteínas Recombinantes/farmacología , Células Tumorales Cultivadas , Neoplasias de la Vejiga Urinaria/metabolismoRESUMEN
A new human myeloid cell line has been established recently from the bone marrow cells of a patient with chronic myelogenous leukemia in blast crisis. The active proliferation and survival of the cells in RPMI 1640 medium containing fetal calf serum are clearly dependent on the presence of either natural or recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Despite permanent culturing in rhGM-CSF (100 U/mL), the cells do not differentiate and bear the myelomonocytic surface markers CD34, CD13, CD36, as well as HLA-DR, but not CD3, CD7, CD10, CD11b, CD14, CD20, or CD42b. The predominant karyotype, apart from tetraploidy in several cells, is 45, XX, -9, -17, -19, -22, 7p-, 9q+ (der t[9;22]), der (13q), with three additional marker chromosomes, from which one was observed in the patient's leukemic cells. On BglII-digested DNA, Southern blot analysis with bcr 5' as the probe detected two additional hybridizing restriction fragments of 8.6 and 11.0 kilobase pairs.
Asunto(s)
Médula Ósea/patología , Factores Estimulantes de Colonias/fisiología , Sustancias de Crecimiento/fisiología , Leucemia Mielógena Crónica BCR-ABL Positiva/patología , Crisis Blástica/patología , Southern Blotting , Médula Ósea/efectos de los fármacos , Médula Ósea/fisiopatología , Línea Celular , Factores Estimulantes de Colonias/análisis , ADN/análisis , ADN/genética , Femenino , Factor Estimulante de Colonias de Granulocitos y Macrófagos , Sustancias de Crecimiento/análisis , Humanos , Cariotipificación , Leucemia Mielógena Crónica BCR-ABL Positiva/genética , Leucemia Mielógena Crónica BCR-ABL Positiva/fisiopatología , Persona de Mediana Edad , FenotipoRESUMEN
By making use of the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) reducing ability of stimulated human neutrophils, we developed an alternative method to quantify the adherence of neutrophils in vitro. After discarding non-adherent neutrophils, the adherent cells were exposed to MTT solution containing 10 ng/ml phorbol 12-myristate 13-acetone (PMA). Subsequently, MTT reduced by this simultaneous stimulation was measured optically and used to calculate percent of adhesion. In these experiments, heat-inactivated autologous serum and tumor necrosis factor alpha (rhTNF-alpha) were observed to promote the adherence to polystyrene surfaces. In contrast, minimal or no effects on neutrophil adherence were achieved in case of treatment with native autologous serum, recombinant human granulocyte colony stimulating factor (rhG-CSF), recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), or recombinant human interferon gamma (rhIFN-gamma).
Asunto(s)
Neutrófilos/fisiología , Bioensayo , Fenómenos Fisiológicos Sanguíneos , Adhesión Celular , Factores Estimulantes de Colonias/fisiología , Colorantes , Factor Estimulante de Colonias de Granulocitos , Factor Estimulante de Colonias de Granulocitos y Macrófagos , Sustancias de Crecimiento/fisiología , Humanos , Interferón gamma/fisiología , Recuento de Leucocitos , Reproducibilidad de los Resultados , Sales de Tetrazolio , Tiazoles , Factor de Necrosis Tumoral alfa/fisiologíaRESUMEN
The colorimetric assay previously described by Mosmann for the measurement of cell viability and proliferation has been modified for the assessment of the functional state of human polymorphnuclear cells (PMNs). The ability of PMNs to reduce the tetrazolium salt MTT to formazan reflects directly the degree of stimulation induced by various agents. The underlying mechanism of MTT-reduction to formazan seems to be similar to that of nitroblue tetrazolium (NBT)-reduction. In contrast to the NBT-reduction assay, the formazan produced from MTT can easily be measured by an ELISA reader. Parallel experiments revealed a qualitative correlation between the concentration of formazan produced from MTT and the concentration of cytochrome C reduced by PMNs. Although oxidative burst may not be the actual lytic mechanism in cellular cytotoxicity of PMN, we also observed an association between MTT-reduction capacity and the cytotoxic activity of PMNs from normal donors in antibody dependent cellular cytotoxicity. Our results indicate that the MTT-reduction assay can be employed to estimate the functional state of polymorphnuclear granulocytes.
Asunto(s)
Neutrófilos/fisiología , División Celular , Supervivencia Celular , Humanos , Peróxido de Hidrógeno/metabolismo , Neutrófilos/citología , Oxidación-Reducción , Oxígeno/fisiología , Sales de Tetrazolio/metabolismo , Tiazoles/metabolismoRESUMEN
Natural killer cell cytotoxic factor (NKCF), a cytotoxic factor contributing to human natural killer cell-mediated cytotoxicity, was generated from lymphocyte-conditioned medium using various stimuli. Crude NKCF activity was concentrated, and partially purified by ammonium sulfate precipitation and gel filtration. NKCF activities eluted as two molecular weight peaks, corresponding to Mr 33,000-43,000 (pool I) and approximately Mr 5,000 (pool II). The cytotoxic activity and target specificity of the partially purified NKCFs were found to be different from both recombinant human TNF and recombinant human lymphotoxin. In the NKCF assay, up to 10(6) units/ml of TNF and lymphotoxin had virtually no effect, whereas both NKCFs lysed 22% (range 17-33%) of the NK-sensitive target K562. In contrast, TNF and lymphotoxin were active in a standard assay against the sensitive murine L929 fibroblast cell line in all concentrations tested (10(-1)-10(6) units/ml). In addition, the effect of these cytotoxic factors in a short-term (4-h) chromium-release assay using peripheral blood mononuclear cells as effector cells was tested: only NKCF (pool I), but not TNF, lymphotoxin, or low molecular weight NKCF (pool II), enhanced NK and lymphokine-activated killer cell cytolysis, both against the NK-sensitive target K562 and the NK-resistant melanoma cell line SK-MEL 30. Results were not affected in the presence of neutralizing antibodies against TNF. NKCF could, therefore, be distinguished from TNF and lymphotoxin with respect to their biological activities.
Asunto(s)
Citotoxicidad Inmunológica , Células Asesinas Naturales/inmunología , Linfotoxina-alfa/inmunología , Proteínas/inmunología , Proteínas Recombinantes/inmunología , Factor de Necrosis Tumoral alfa/inmunología , Línea Celular , Pruebas Inmunológicas de Citotoxicidad , Relación Dosis-Respuesta a Droga , Humanos , Interferón Tipo I/inmunología , Interleucina-2/inmunología , Factores Asesinos de Levadura , Pruebas de Neutralización , Proteínas/aislamiento & purificaciónRESUMEN
Human pluripotent colony stimulating factor (Pluripoietin) was shown to act synergistically with human pluripotent alpha-like colony-stimulating activity (Pluripoietin-alpha) supporting the proliferation and differentiation of human CFU-GM progenitor cells in vitro, increasing colony size and numbers. In addition, Pluripoietin enhanced cytotoxic activity of mature human neutrophil granulocytes in an antibody-dependent cellular cytotoxicity assay. Biological activities of Pluripoietin known so far suggest great potentials for clinical use. Preclinical in vivo studies of Pluripoietin in different disease situations may be feasible in mice, because Pluripoietin is active on granulocyte precursors and on a variety of other murine cells.